ライフサイエンスコーパス: fluid loss

1 ers at 24 h, despite greater weight loss and fluid loss.

2 t rapidly initiate inflammation and vascular fluid loss.

3 al increase in protein concentrations due to fluid loss.

4 icate the intestinal lumen while restricting fluid loss.

5 his is a novel mechanism to limit intestinal fluid loss.

6 ime it is in place, decreasing cerebrospinal fluid loss.

7 layer, the osmotic pressure of which opposes fluid loss.

8 n epidermal barrier function to prevent body fluid loss.

9 tate rehydration efforts by limiting further fluid losses.

10 min, at a rate that replaced a third of the fluid losses.

11 ortant to ensure compensation for extrarenal fluid losses.

12 d is distinct from hypovolemia due to excess fluid losses.

13 .1 kg vs. 3.1 +/- 3.5 kg; p = 0.001) and net fluid loss (4.6 vs. 3.3 l; p = 0.001) were greater in th

14 protein (1.5 vs. 0.5 g/dL at day 3), and net fluid loss (-5480 vs. -1490 mL at day 3) throughout the

15 r properties and can result in intravascular fluid loss and edema.

16 al and viral diseases consists of correcting fluid loss and electrolyte imbalance by oral or parenter

17 T-L4-deficient newborn mice had greater body fluid loss and higher mortality in a trans-epidermal bod

18 a physiological role for NDR1 in preventing fluid loss and maintaining cell integrity through plasma

19 osemide with placebo for 72 hrs, titrated to fluid loss and normalization of serum total protein conc

20 In humans, drinking replenishes fluid loss and satiates the sensation of thirst that acc

21 orrelation between either weight loss or net fluid loss and symptom relief, (r=0.04; P=0.54 and r=0.0

22 Weight loss, fluid loss, and NT-proBNP reduction at 72 hours are poor

23 of decongestion at 72 hours-weight loss, net fluid loss, and percent reduction in serum N terminal B-

24 Secondary end points included net fluid loss at 48 h, functional capacity, HF rehospitaliz

25 ptan resulted in greater weight loss and net fluid loss compared with placebo, but tolvaptan-treated

26 nown regarding innate mechanisms that dampen fluid loss during PMN-endothelial interactions.

27 from serial measurements are consistent with fluid loss for both ED and ID conditions.

28 he drug concentration dilution caused by the fluid loss from blood stream in the tumour region around

29 polysaccharide of synovial fluid, attenuates fluid loss from joints as joint pressure is raised ('out

30 (HA), a component of synovial fluid, buffers fluid loss from joints.

31 ease at early times after CA-4-P, suggesting fluid loss from the blood.

32 s the toxin responsible for inducing massive fluid loss from the human host.

33 n NHE3-dependent manner and restored the net fluid loss in a mouse model of acute diarrhea.

34 f cystic fibrosis and in reducing intestinal fluid loss in cholera and other secretory diarrheas.

35 Ou and FVB/N was associated with significant fluid loss in feces, a remarkable downregulation of Slc2

36 toxins may cause life-threatening diarrhoeal fluid loss in part because they stimulate enterocytes to

37 ycystic kidney disease and reduce intestinal fluid loss in secretory diarrheas.

38 of CaCC functions and in reducing intestinal fluid losses in CaCC-mediated secretory diarrheas.

39 CFTR inhibition might also reduce intestinal fluid losses in cholera and possibly in other infectious

40 ntoxic CFTR inhibitors may reduce intestinal fluid losses in cholera.

41 retion accounted for less than 30% of plasma fluid loss indicating that reduced albumin permeability

42 cluding depressing stroke volume, increasing fluid loss into the intestine, and increasing inflammato

43 inking water in response to thirst following fluid loss is a pleasant experience.

44 ough the assessment of daily weights and net fluid loss is the current standard of care, yet the rela

45 % confidence interval, 0.90-0.99 per 1000 mL fluid loss; NT-proBNP hazard ratio, 0.95; 95% confidence

46 free balanced crystalloid for replacement of fluid losses on the day of major surgery was associated

47 uantitative projections of fluid therapy and fluid losses on the patient's serum sodium, balances pot

48 cation and greatly attenuates trans-synovial fluid loss (outflow buffering).

49 d higher mortality in a trans-epidermal body fluid loss test.

50 iltration safely produces greater weight and fluid loss than intravenous diuretics, reduces 90-day re